Johnson & Johnson's IL-23 inhibitor Tremfya has been approved by the FDA as a treatment for Crohn's disease, becoming the ...

The FDA expanded the approval of guselkumab (Tremfya) to include treatment of moderately to severely active Crohn's disease, ...

With another inflammatory bowel disease (IBD) approval in the bag for Tremfya, Johnson & Johnson continues to make good on ...

The FDA has approved Tremfya as the “first and only” interleukin-23 inhibitor that offers both IV and fully subcutaneous ...

Johnson & Johnson JNJ announced that the FDA has granted approval to its key drug, Tremfya, for its second inflammatory bowel disease (IBD) condition — moderately to severely active Crohn’s disease ...

and AbbVie’s Skyrizi (risankizumab). Both drugs brought in $132m and $11bn respectively, however, both currently rely on an initial intravenous infusion. J&J’s competition does have the edge ...

induction therapy to eliminate the need for in-clinic IV infusions required for Skyrizi and Omvoh. The ASTRO trial, whose full results will be revealed at ECCO 2025, has already demonstrated ...

So if you're talking about healthy volunteer studies, so if you look at data from a publication from Regeneron, they showed for example that Dupilumab dose, in a dose response manner both IV and ...